 Thomas Kelly Jr
Concepts (423)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Serine Endopeptidases | 11 | 2016 | 50 | 1.850 |
Why?
| | Gelatinases | 11 | 2016 | 32 | 1.830 |
Why?
| | Membrane Proteins | 16 | 2023 | 344 | 1.690 |
Why?
| | Schizosaccharomyces | 5 | 2019 | 59 | 1.610 |
Why?
| | Breast Neoplasms | 14 | 2024 | 1203 | 1.380 |
Why?
| | DNA Replication | 5 | 2019 | 159 | 1.020 |
Why?
| | Neoplasm Invasiveness | 9 | 2016 | 278 | 0.840 |
Why?
| | Cricetulus | 1 | 2024 | 100 | 0.840 |
Why?
| | Glucuronidase | 5 | 2010 | 47 | 0.800 |
Why?
| | Students, Medical | 1 | 2023 | 157 | 0.710 |
Why?
| | Eukaryotic Cells | 2 | 2019 | 14 | 0.650 |
Why?
| | Propylene Glycol | 1 | 2018 | 1 | 0.590 |
Why?
| | Glycerol | 1 | 2018 | 19 | 0.590 |
Why?
| | Animals | 34 | 2024 | 13485 | 0.580 |
Why?
| | Neoplasms | 4 | 2023 | 1314 | 0.560 |
Why?
| | DNA Damage | 3 | 2016 | 298 | 0.560 |
Why?
| | Neoplasm Metastasis | 8 | 2011 | 235 | 0.540 |
Why?
| | DNA, Fungal | 2 | 2016 | 43 | 0.540 |
Why?
| | Endopeptidases | 13 | 2016 | 62 | 0.540 |
Why?
| | Biomedical Research | 2 | 2014 | 260 | 0.530 |
Why?
| | Cocaine | 3 | 2023 | 168 | 0.520 |
Why?
| | Ultraviolet Rays | 2 | 2007 | 50 | 0.520 |
Why?
| | Adenocarcinoma | 3 | 2005 | 403 | 0.510 |
Why?
| | Body Composition | 3 | 2023 | 343 | 0.510 |
Why?
| | DNA Repair | 2 | 2016 | 194 | 0.500 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 9 | 0.490 |
Why?
| | Gene Expression Regulation, Fungal | 1 | 2016 | 51 | 0.470 |
Why?
| | Humans | 54 | 2024 | 52441 | 0.470 |
Why?
| | Smoking | 1 | 2018 | 514 | 0.450 |
Why?
| | Origin Recognition Complex | 2 | 2019 | 6 | 0.440 |
Why?
| | Proteoglycans | 5 | 2023 | 86 | 0.440 |
Why?
| | Extracellular Matrix | 6 | 2005 | 116 | 0.430 |
Why?
| | Syndecan-1 | 4 | 2010 | 73 | 0.430 |
Why?
| | Medical Oncology | 2 | 2023 | 97 | 0.420 |
Why?
| | Cell Movement | 4 | 2019 | 271 | 0.400 |
Why?
| | Cell Line, Tumor | 10 | 2020 | 1429 | 0.400 |
Why?
| | Body Water | 2 | 2023 | 26 | 0.400 |
Why?
| | Schizosaccharomyces pombe Proteins | 4 | 2019 | 42 | 0.390 |
Why?
| | Mice | 12 | 2023 | 5899 | 0.360 |
Why?
| | Disease | 1 | 2012 | 26 | 0.360 |
Why?
| | Cellular Microenvironment | 1 | 2012 | 29 | 0.360 |
Why?
| | Cell Membrane | 9 | 2005 | 238 | 0.350 |
Why?
| | Dopaminergic Neurons | 4 | 2023 | 19 | 0.350 |
Why?
| | Female | 27 | 2024 | 28277 | 0.340 |
Why?
| | Cell Cycle Proteins | 3 | 2020 | 168 | 0.340 |
Why?
| | Vulvar Neoplasms | 3 | 2016 | 60 | 0.340 |
Why?
| | Antigens, Neoplasm | 2 | 2011 | 145 | 0.340 |
Why?
| | Fructose | 1 | 2010 | 21 | 0.330 |
Why?
| | Dipeptidyl Peptidase 4 | 3 | 2011 | 9 | 0.330 |
Why?
| | Stromal Cells | 3 | 2016 | 76 | 0.330 |
Why?
| | Carbon | 1 | 2010 | 60 | 0.320 |
Why?
| | Cytoskeletal Proteins | 3 | 2020 | 47 | 0.310 |
Why?
| | Transfection | 4 | 2024 | 365 | 0.310 |
Why?
| | Multiple Myeloma | 6 | 2004 | 3013 | 0.300 |
Why?
| | Neovascularization, Pathologic | 3 | 2005 | 158 | 0.300 |
Why?
| | Membrane Glycoproteins | 6 | 2005 | 239 | 0.300 |
Why?
| | Cell Cycle | 2 | 2007 | 236 | 0.290 |
Why?
| | Bone and Bones | 2 | 2010 | 492 | 0.290 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2016 | 331 | 0.290 |
Why?
| | Heparan Sulfate Proteoglycans | 2 | 2005 | 12 | 0.280 |
Why?
| | Mammary Neoplasms, Experimental | 2 | 2005 | 122 | 0.270 |
Why?
| | Osteogenesis | 1 | 2010 | 368 | 0.270 |
Why?
| | Tumor Cells, Cultured | 7 | 2010 | 441 | 0.270 |
Why?
| | Osteoclasts | 1 | 2010 | 423 | 0.270 |
Why?
| | Bone Resorption | 2 | 2010 | 300 | 0.260 |
Why?
| | Cell Adhesion | 7 | 2020 | 162 | 0.260 |
Why?
| | RNA, Messenger | 4 | 2023 | 1134 | 0.260 |
Why?
| | Bone Neoplasms | 2 | 2005 | 188 | 0.240 |
Why?
| | Mice, SCID | 4 | 2010 | 178 | 0.240 |
Why?
| | Oligosaccharides | 1 | 2005 | 33 | 0.240 |
Why?
| | Antibodies, Neoplasm | 1 | 2005 | 27 | 0.240 |
Why?
| | Models, Biological | 4 | 2019 | 735 | 0.230 |
Why?
| | Peripheral Nerves | 2 | 2015 | 47 | 0.230 |
Why?
| | DNA | 1 | 2008 | 544 | 0.230 |
Why?
| | Nanostructures | 1 | 2005 | 41 | 0.230 |
Why?
| | Education, Medical, Undergraduate | 1 | 2006 | 86 | 0.230 |
Why?
| | Pseudohypoaldosteronism | 1 | 2024 | 8 | 0.220 |
Why?
| | Receptors, Mineralocorticoid | 1 | 2024 | 12 | 0.220 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2019 | 853 | 0.220 |
Why?
| | Clone Cells | 1 | 2024 | 76 | 0.210 |
Why?
| | Drug Industry | 1 | 2024 | 39 | 0.210 |
Why?
| | CHO Cells | 1 | 2024 | 123 | 0.210 |
Why?
| | Extinction, Psychological | 1 | 2023 | 34 | 0.200 |
Why?
| | Metalloendopeptidases | 3 | 1998 | 70 | 0.200 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2023 | 64 | 0.200 |
Why?
| | Research | 1 | 2023 | 109 | 0.200 |
Why?
| | Actins | 5 | 2020 | 112 | 0.200 |
Why?
| | Fear | 1 | 2023 | 84 | 0.190 |
Why?
| | Serotonin | 1 | 2023 | 149 | 0.190 |
Why?
| | Cell Proliferation | 5 | 2019 | 1013 | 0.190 |
Why?
| | Parkinson Disease, Secondary | 1 | 2021 | 7 | 0.180 |
Why?
| | Program Evaluation | 1 | 2023 | 351 | 0.180 |
Why?
| | Pyrans | 1 | 2021 | 16 | 0.180 |
Why?
| | Drug-Seeking Behavior | 1 | 2021 | 4 | 0.180 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2021 | 22 | 0.180 |
Why?
| | Telomerase | 1 | 2021 | 26 | 0.180 |
Why?
| | Bone Density | 1 | 2023 | 396 | 0.180 |
Why?
| | Reinforcement Schedule | 1 | 2021 | 72 | 0.180 |
Why?
| | Collagenases | 2 | 1999 | 24 | 0.180 |
Why?
| | Cues | 1 | 2021 | 53 | 0.170 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2021 | 57 | 0.170 |
Why?
| | Neoplasm Proteins | 4 | 1998 | 328 | 0.170 |
Why?
| | Internal Mammary-Coronary Artery Anastomosis | 1 | 2020 | 5 | 0.170 |
Why?
| | Curriculum | 1 | 2023 | 406 | 0.170 |
Why?
| | Radial Artery | 1 | 2020 | 34 | 0.170 |
Why?
| | Behavior, Animal | 1 | 2021 | 190 | 0.170 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2021 | 132 | 0.160 |
Why?
| | Pyrimidines | 1 | 2021 | 199 | 0.160 |
Why?
| | Collagen Type I | 2 | 2016 | 83 | 0.160 |
Why?
| | Pyridines | 1 | 2021 | 137 | 0.160 |
Why?
| | Neurons | 1 | 2023 | 442 | 0.160 |
Why?
| | Cyclin-Dependent Kinase 5 | 1 | 2020 | 1 | 0.160 |
Why?
| | Matrix Metalloproteinases | 1 | 2000 | 47 | 0.160 |
Why?
| | Actin Cytoskeleton | 1 | 2020 | 22 | 0.160 |
Why?
| | Signal Transduction | 7 | 2020 | 1724 | 0.160 |
Why?
| | Immunohistochemistry | 5 | 2016 | 977 | 0.160 |
Why?
| | Cyclic AMP | 1 | 2020 | 90 | 0.160 |
Why?
| | Cocaine-Related Disorders | 1 | 2021 | 206 | 0.150 |
Why?
| | Lung Neoplasms | 1 | 2005 | 643 | 0.150 |
Why?
| | Parkinson Disease | 1 | 2021 | 168 | 0.150 |
Why?
| | Electric Impedance | 3 | 2023 | 48 | 0.150 |
Why?
| | AT Rich Sequence | 1 | 2019 | 1 | 0.150 |
Why?
| | DNA Replication Timing | 1 | 2019 | 1 | 0.150 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2019 | 11 | 0.150 |
Why?
| | Chromosomes, Fungal | 1 | 2019 | 13 | 0.150 |
Why?
| | Genome, Fungal | 1 | 2019 | 29 | 0.150 |
Why?
| | Cell Division | 3 | 2004 | 288 | 0.150 |
Why?
| | Pharmaceutical Solutions | 1 | 2018 | 9 | 0.150 |
Why?
| | Pancreas | 1 | 2019 | 71 | 0.150 |
Why?
| | Sensation | 1 | 2018 | 11 | 0.150 |
Why?
| | Stimulation, Chemical | 1 | 2018 | 30 | 0.150 |
Why?
| | Drug Compounding | 1 | 2018 | 26 | 0.150 |
Why?
| | Ventral Tegmental Area | 3 | 2023 | 8 | 0.150 |
Why?
| | Probability | 1 | 2019 | 171 | 0.150 |
Why?
| | Plants | 1 | 2018 | 28 | 0.140 |
Why?
| | Male | 10 | 2024 | 26874 | 0.140 |
Why?
| | Aerosols | 1 | 2018 | 74 | 0.140 |
Why?
| | Mice, Inbred BALB C | 2 | 2011 | 304 | 0.140 |
Why?
| | Protein Processing, Post-Translational | 1 | 2019 | 152 | 0.140 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2019 | 187 | 0.140 |
Why?
| | Computer Simulation | 1 | 2019 | 285 | 0.140 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 1998 | 89 | 0.140 |
Why?
| | Phenotype | 3 | 2010 | 792 | 0.140 |
Why?
| | Adult | 9 | 2023 | 14205 | 0.140 |
Why?
| | Transcription, Genetic | 1 | 2019 | 375 | 0.130 |
Why?
| | Isotonic Solutions | 1 | 2017 | 21 | 0.130 |
Why?
| | Young Adult | 4 | 2023 | 4346 | 0.130 |
Why?
| | Fluid Therapy | 1 | 2017 | 80 | 0.130 |
Why?
| | Coronary Artery Disease | 1 | 2020 | 323 | 0.130 |
Why?
| | Phosphorylation | 3 | 2020 | 536 | 0.120 |
Why?
| | Pancreatitis | 1 | 2017 | 66 | 0.120 |
Why?
| | Time-Lapse Imaging | 1 | 2016 | 3 | 0.120 |
Why?
| | Blood Pressure | 1 | 2018 | 525 | 0.120 |
Why?
| | Secretory Leukocyte Peptidase Inhibitor | 1 | 2015 | 1 | 0.120 |
Why?
| | Rad51 Recombinase | 1 | 2016 | 28 | 0.120 |
Why?
| | Nucleotidyltransferases | 1 | 2016 | 16 | 0.120 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2016 | 56 | 0.120 |
Why?
| | Scavenger Receptors, Class A | 1 | 2016 | 39 | 0.120 |
Why?
| | Simplexvirus | 1 | 2015 | 17 | 0.120 |
Why?
| | Protein Kinases | 2 | 2006 | 73 | 0.120 |
Why?
| | Virus Internalization | 1 | 2015 | 20 | 0.120 |
Why?
| | Mitosis | 1 | 2016 | 87 | 0.120 |
Why?
| | Cell Transformation, Viral | 3 | 1994 | 25 | 0.120 |
Why?
| | Human papillomavirus 16 | 1 | 2015 | 44 | 0.120 |
Why?
| | Fibroma | 1 | 2015 | 40 | 0.110 |
Why?
| | Syndecans | 4 | 2005 | 37 | 0.110 |
Why?
| | Keratinocytes | 1 | 2015 | 91 | 0.110 |
Why?
| | Models, Organizational | 1 | 2015 | 58 | 0.110 |
Why?
| | Enzyme Activation | 3 | 2006 | 269 | 0.110 |
Why?
| | Avian Sarcoma Viruses | 2 | 1994 | 5 | 0.110 |
Why?
| | DNA-Directed DNA Polymerase | 1 | 2016 | 89 | 0.110 |
Why?
| | Neoplasm Transplantation | 2 | 2005 | 86 | 0.110 |
Why?
| | Transplantation, Heterologous | 2 | 2005 | 78 | 0.110 |
Why?
| | Fibroblasts | 3 | 1994 | 357 | 0.110 |
Why?
| | Extracellular Matrix Proteins | 2 | 1994 | 69 | 0.110 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2015 | 639 | 0.110 |
Why?
| | Host-Pathogen Interactions | 1 | 2015 | 130 | 0.110 |
Why?
| | Peptide Hydrolases | 2 | 1994 | 62 | 0.100 |
Why?
| | Community Pharmacy Services | 1 | 2015 | 71 | 0.100 |
Why?
| | Cytoskeleton | 3 | 1989 | 38 | 0.100 |
Why?
| | Macrophages | 1 | 2016 | 357 | 0.100 |
Why?
| | Absorptiometry, Photon | 2 | 2023 | 161 | 0.100 |
Why?
| | Wnt1 Protein | 1 | 2012 | 10 | 0.100 |
Why?
| | Aged, 80 and over | 5 | 2020 | 3449 | 0.100 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2012 | 33 | 0.100 |
Why?
| | Phytotherapy | 1 | 2012 | 45 | 0.100 |
Why?
| | Cadherins | 3 | 2016 | 61 | 0.100 |
Why?
| | Interleukin-8 | 2 | 2010 | 86 | 0.100 |
Why?
| | Athletes | 2 | 2023 | 105 | 0.090 |
Why?
| | Chick Embryo | 5 | 1999 | 79 | 0.090 |
Why?
| | Serine Proteinase Inhibitors | 1 | 2012 | 12 | 0.090 |
Why?
| | Aged | 8 | 2023 | 10242 | 0.090 |
Why?
| | Organ Specificity | 1 | 2012 | 116 | 0.090 |
Why?
| | Rats | 3 | 2023 | 3228 | 0.090 |
Why?
| | Microscopy, Phase-Contrast | 1 | 2010 | 9 | 0.080 |
Why?
| | Plant Lectins | 1 | 2010 | 8 | 0.080 |
Why?
| | PAX2 Transcription Factor | 1 | 2010 | 24 | 0.080 |
Why?
| | Cell Line | 2 | 2015 | 1020 | 0.080 |
Why?
| | Carcinoma, Papillary | 1 | 2010 | 49 | 0.080 |
Why?
| | Culture Media, Conditioned | 1 | 2010 | 46 | 0.080 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2012 | 196 | 0.080 |
Why?
| | Glycosylation | 1 | 2010 | 104 | 0.080 |
Why?
| | Substrate Specificity | 1 | 2010 | 197 | 0.080 |
Why?
| | Insulin | 1 | 2012 | 485 | 0.080 |
Why?
| | Reproducibility of Results | 2 | 2023 | 1223 | 0.080 |
Why?
| | Acoustics | 1 | 2009 | 17 | 0.080 |
Why?
| | Light | 1 | 2009 | 50 | 0.080 |
Why?
| | Carcinoma, Renal Cell | 1 | 2010 | 112 | 0.080 |
Why?
| | Time Factors | 4 | 2017 | 2987 | 0.080 |
Why?
| | Magnetics | 1 | 2009 | 27 | 0.080 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2009 | 34 | 0.080 |
Why?
| | Analgesics, Opioid | 1 | 2015 | 601 | 0.080 |
Why?
| | Substance-Related Disorders | 1 | 2015 | 615 | 0.080 |
Why?
| | Middle Aged | 8 | 2020 | 13133 | 0.080 |
Why?
| | Kidney Neoplasms | 1 | 2010 | 181 | 0.070 |
Why?
| | Neoplasm Staging | 3 | 2016 | 768 | 0.070 |
Why?
| | DNA, Superhelical | 1 | 2008 | 3 | 0.070 |
Why?
| | DNA Topoisomerases, Type I | 1 | 2008 | 3 | 0.070 |
Why?
| | Salts | 1 | 2008 | 8 | 0.070 |
Why?
| | Protein Structure, Tertiary | 3 | 2005 | 260 | 0.070 |
Why?
| | Replication Origin | 1 | 2008 | 11 | 0.070 |
Why?
| | Amino Acid Motifs | 1 | 2008 | 59 | 0.070 |
Why?
| | Diet | 1 | 2012 | 591 | 0.070 |
Why?
| | Mesoderm | 1 | 2008 | 29 | 0.070 |
Why?
| | Early Detection of Cancer | 1 | 2009 | 185 | 0.070 |
Why?
| | Disease Models, Animal | 2 | 2021 | 1483 | 0.070 |
Why?
| | Muscle, Smooth | 1 | 1987 | 63 | 0.070 |
Why?
| | Integrins | 3 | 2016 | 31 | 0.070 |
Why?
| | Protein Binding | 2 | 2008 | 673 | 0.070 |
Why?
| | Mutation | 2 | 2019 | 1331 | 0.070 |
Why?
| | DNA, Mitochondrial | 1 | 2008 | 112 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 580 | 0.070 |
Why?
| | Glycoproteins | 1 | 1987 | 123 | 0.070 |
Why?
| | Epithelial Cells | 1 | 2008 | 217 | 0.060 |
Why?
| | Breast | 2 | 2016 | 86 | 0.060 |
Why?
| | Treatment Outcome | 4 | 2020 | 5508 | 0.060 |
Why?
| | Blotting, Western | 3 | 2012 | 587 | 0.060 |
Why?
| | DNA, Complementary | 2 | 2004 | 129 | 0.060 |
Why?
| | Lymphatic Metastasis | 2 | 2015 | 210 | 0.060 |
Why?
| | Dimerization | 1 | 2006 | 51 | 0.060 |
Why?
| | Catalytic Domain | 1 | 2006 | 61 | 0.060 |
Why?
| | Pancreatic Neoplasms | 1 | 2008 | 208 | 0.060 |
Why?
| | E-Selectin | 1 | 2005 | 11 | 0.060 |
Why?
| | Metals | 1 | 2005 | 37 | 0.060 |
Why?
| | Phototherapy | 1 | 2005 | 26 | 0.060 |
Why?
| | Chi-Square Distribution | 2 | 2016 | 292 | 0.060 |
Why?
| | Ligands | 1 | 2005 | 205 | 0.060 |
Why?
| | Immunoblotting | 2 | 2003 | 118 | 0.060 |
Why?
| | Fungal Proteins | 1 | 2006 | 114 | 0.060 |
Why?
| | Carcinogens | 2 | 2005 | 194 | 0.060 |
Why?
| | Heparitin Sulfate | 1 | 2004 | 7 | 0.060 |
Why?
| | Fibronectins | 2 | 1998 | 36 | 0.060 |
Why?
| | Gold | 1 | 2005 | 81 | 0.060 |
Why?
| | Career Choice | 1 | 2006 | 117 | 0.060 |
Why?
| | Antibodies, Monoclonal | 3 | 2023 | 475 | 0.050 |
Why?
| | Hyperthermia, Induced | 1 | 2005 | 114 | 0.050 |
Why?
| | Matrix Metalloproteinase 9 | 3 | 2002 | 88 | 0.050 |
Why?
| | Growth Substances | 2 | 2003 | 22 | 0.050 |
Why?
| | Microscopy, Fluorescence | 2 | 2003 | 140 | 0.050 |
Why?
| | Osteolysis | 1 | 2004 | 74 | 0.050 |
Why?
| | Optical Imaging | 1 | 2023 | 25 | 0.050 |
Why?
| | Microfilament Proteins | 2 | 2020 | 44 | 0.050 |
Why?
| | Odds Ratio | 2 | 2015 | 563 | 0.050 |
Why?
| | Cells, Cultured | 4 | 2016 | 1583 | 0.050 |
Why?
| | Receptors, Lipoprotein | 1 | 2003 | 7 | 0.050 |
Why?
| | Lipoproteins, HDL | 1 | 2003 | 16 | 0.050 |
Why?
| | Gene Deletion | 1 | 2024 | 279 | 0.050 |
Why?
| | Receptors, Immunologic | 1 | 2003 | 35 | 0.050 |
Why?
| | Nitric Oxide Synthase | 1 | 2003 | 72 | 0.050 |
Why?
| | Vimentin | 2 | 2016 | 31 | 0.050 |
Why?
| | Chondroitin Sulfate Proteoglycans | 1 | 2023 | 18 | 0.050 |
Why?
| | Blotting, Northern | 1 | 2003 | 107 | 0.050 |
Why?
| | Oligonucleotides, Antisense | 1 | 2003 | 29 | 0.050 |
Why?
| | Antigens, Tumor-Associated, Carbohydrate | 1 | 2023 | 24 | 0.050 |
Why?
| | Muscle Strength | 1 | 2023 | 132 | 0.050 |
Why?
| | Indicator Dilution Techniques | 1 | 2022 | 13 | 0.050 |
Why?
| | Deuterium Oxide | 1 | 2022 | 10 | 0.050 |
Why?
| | Logistic Models | 2 | 2015 | 930 | 0.050 |
Why?
| | Cloning, Molecular | 1 | 2003 | 181 | 0.050 |
Why?
| | Cell Separation | 1 | 2003 | 78 | 0.050 |
Why?
| | Deuterium | 1 | 2022 | 47 | 0.050 |
Why?
| | Mesencephalon | 1 | 2022 | 36 | 0.050 |
Why?
| | Mucous Membrane | 1 | 2002 | 33 | 0.050 |
Why?
| | Models, Genetic | 1 | 2003 | 173 | 0.050 |
Why?
| | Molecular Weight | 3 | 1994 | 78 | 0.050 |
Why?
| | Rectum | 1 | 2002 | 55 | 0.050 |
Why?
| | Oxidopamine | 1 | 2021 | 3 | 0.050 |
Why?
| | Bone Marrow | 1 | 2003 | 354 | 0.050 |
Why?
| | Telomere-Binding Proteins | 1 | 2021 | 8 | 0.050 |
Why?
| | Up-Regulation | 1 | 2023 | 462 | 0.050 |
Why?
| | Rats, Long-Evans | 1 | 2021 | 23 | 0.050 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 257 | 0.050 |
Why?
| | Estradiol | 1 | 2003 | 226 | 0.050 |
Why?
| | Dopamine | 1 | 2022 | 170 | 0.040 |
Why?
| | Telomere | 1 | 2021 | 39 | 0.040 |
Why?
| | Carcinoma | 1 | 2003 | 135 | 0.040 |
Why?
| | Self Administration | 1 | 2021 | 90 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2003 | 263 | 0.040 |
Why?
| | Neuronal Plasticity | 1 | 2021 | 57 | 0.040 |
Why?
| | Biopsy | 2 | 2015 | 594 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2003 | 396 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2005 | 1004 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2020 | 6694 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2021 | 141 | 0.040 |
Why?
| | Neuroprotective Agents | 1 | 2021 | 103 | 0.040 |
Why?
| | Saccharomyces cerevisiae | 1 | 2021 | 168 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2021 | 150 | 0.040 |
Why?
| | Australia | 1 | 2020 | 97 | 0.040 |
Why?
| | Actin Depolymerizing Factors | 1 | 2020 | 5 | 0.040 |
Why?
| | Thiazolidines | 1 | 2020 | 5 | 0.040 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2020 | 17 | 0.040 |
Why?
| | Recombinant Proteins | 2 | 2016 | 490 | 0.040 |
Why?
| | Propensity Score | 1 | 2020 | 160 | 0.040 |
Why?
| | Collagen | 2 | 1998 | 215 | 0.040 |
Why?
| | Stress Fibers | 1 | 2019 | 5 | 0.040 |
Why?
| | HeLa Cells | 1 | 2020 | 243 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2020 | 236 | 0.040 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2019 | 14 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2019 | 47 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2019 | 48 | 0.040 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2019 | 25 | 0.040 |
Why?
| | Evaluation Studies as Topic | 1 | 1999 | 101 | 0.040 |
Why?
| | Bone Remodeling | 1 | 2000 | 151 | 0.040 |
Why?
| | Pseudopodia | 1 | 1998 | 5 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2003 | 1099 | 0.040 |
Why?
| | Prostatic Neoplasms | 1 | 2002 | 398 | 0.040 |
Why?
| | RNA, Small Interfering | 1 | 2019 | 217 | 0.040 |
Why?
| | Thiophenes | 1 | 1998 | 45 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2021 | 1365 | 0.040 |
Why?
| | Linear Models | 1 | 1999 | 288 | 0.040 |
Why?
| | Survival Rate | 1 | 2020 | 944 | 0.030 |
Why?
| | Phenylalanine | 1 | 1998 | 139 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2005 | 1216 | 0.030 |
Why?
| | Databases, Factual | 1 | 2020 | 721 | 0.030 |
Why?
| | Blood Urea Nitrogen | 1 | 2017 | 40 | 0.030 |
Why?
| | Hematocrit | 1 | 2017 | 42 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2024 | 2871 | 0.030 |
Why?
| | Creatinine | 1 | 2017 | 156 | 0.030 |
Why?
| | Risk Factors | 2 | 2015 | 3971 | 0.030 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2017 | 63 | 0.030 |
Why?
| | Lymph Nodes | 1 | 1998 | 253 | 0.030 |
Why?
| | Abdominal Pain | 1 | 2017 | 83 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 1998 | 378 | 0.030 |
Why?
| | Pain Measurement | 1 | 2017 | 263 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 384 | 0.030 |
Why?
| | Anion Exchange Protein 1, Erythrocyte | 1 | 2015 | 8 | 0.030 |
Why?
| | beta Catenin | 1 | 2016 | 105 | 0.030 |
Why?
| | Antiporters | 1 | 2015 | 19 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2016 | 1888 | 0.030 |
Why?
| | S100 Proteins | 1 | 2015 | 33 | 0.030 |
Why?
| | Antigens, CD | 1 | 2016 | 213 | 0.030 |
Why?
| | Professional Role | 1 | 2015 | 79 | 0.030 |
Why?
| | Neoplasm, Residual | 1 | 2015 | 169 | 0.030 |
Why?
| | Down-Regulation | 1 | 2015 | 348 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2015 | 601 | 0.030 |
Why?
| | Protease Inhibitors | 1 | 1994 | 60 | 0.030 |
Why?
| | Pharmacists | 1 | 2015 | 150 | 0.030 |
Why?
| | Patient-Centered Care | 1 | 2015 | 141 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2017 | 1045 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 134 | 0.020 |
Why?
| | Lactation | 1 | 2012 | 61 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 870 | 0.020 |
Why?
| | Adolescent | 1 | 2023 | 6713 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 182 | 0.020 |
Why?
| | Cell Nucleus | 2 | 2010 | 189 | 0.020 |
Why?
| | Melanoma | 1 | 1994 | 272 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2012 | 566 | 0.020 |
Why?
| | Cross Reactions | 2 | 1987 | 43 | 0.020 |
Why?
| | Rheology | 1 | 2009 | 4 | 0.020 |
Why?
| | Molecular Mimicry | 1 | 2009 | 35 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 2 | 2002 | 59 | 0.020 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2008 | 29 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2010 | 871 | 0.020 |
Why?
| | Nanoparticles | 1 | 2009 | 131 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 938 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 1987 | 62 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2008 | 136 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2010 | 1028 | 0.020 |
Why?
| | Chickens | 1 | 1987 | 107 | 0.020 |
Why?
| | Kidney | 1 | 2010 | 716 | 0.020 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2005 | 35 | 0.020 |
Why?
| | Pregnancy | 1 | 2012 | 2642 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 186 | 0.010 |
Why?
| | Scavenger Receptors, Class B | 1 | 2003 | 13 | 0.010 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2003 | 62 | 0.010 |
Why?
| | Receptors, Scavenger | 1 | 2003 | 29 | 0.010 |
Why?
| | Hormone Replacement Therapy | 1 | 2003 | 25 | 0.010 |
Why?
| | Ovariectomy | 1 | 2003 | 115 | 0.010 |
Why?
| | Spectrin | 1 | 1982 | 3 | 0.010 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2003 | 83 | 0.010 |
Why?
| | Brain Chemistry | 1 | 1982 | 70 | 0.010 |
Why?
| | Vasodilation | 1 | 2003 | 99 | 0.010 |
Why?
| | Femoral Artery | 1 | 2003 | 104 | 0.010 |
Why?
| | Protein Transport | 1 | 2003 | 172 | 0.010 |
Why?
| | Endoscopy | 1 | 2002 | 126 | 0.010 |
Why?
| | Neutrophils | 1 | 2002 | 148 | 0.010 |
Why?
| | Sex Factors | 1 | 2003 | 735 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2003 | 903 | 0.010 |
Why?
| | beta 2-Microglobulin | 1 | 1997 | 39 | 0.010 |
Why?
| | Rhodamines | 1 | 1993 | 4 | 0.010 |
Why?
| | Cell Adhesion Molecules | 1 | 1994 | 89 | 0.010 |
Why?
| | Tissue Inhibitor of Metalloproteinase-2 | 1 | 1993 | 11 | 0.010 |
Why?
| | Gelatin | 1 | 1993 | 22 | 0.010 |
Why?
| | Biotin | 1 | 1993 | 46 | 0.010 |
Why?
| | Binding Sites | 1 | 1993 | 379 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1993 | 576 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1993 | 778 | 0.010 |
Why?
| | Talin | 1 | 1989 | 3 | 0.010 |
Why?
| | Concanavalin A | 1 | 1989 | 10 | 0.010 |
Why?
| | Microspheres | 1 | 1989 | 20 | 0.000 |
Why?
| | Cell Line, Transformed | 1 | 1989 | 74 | 0.000 |
Why?
| | Vinculin | 1 | 1982 | 3 | 0.000 |
Why?
| | Immune Sera | 1 | 1982 | 15 | 0.000 |
Why?
| | Actinin | 1 | 1982 | 4 | 0.000 |
Why?
| | Erythrocyte Membrane | 1 | 1982 | 14 | 0.000 |
Why?
| | Ankyrins | 1 | 1982 | 9 | 0.000 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1982 | 95 | 0.000 |
Why?
| | Fluorescent Antibody Technique | 1 | 1982 | 110 | 0.000 |
Why?
| | Epitopes | 1 | 1982 | 62 | 0.000 |
Why?
| | Cattle | 1 | 1982 | 197 | 0.000 |
Why?
| | Terminology as Topic | 1 | 1982 | 69 | 0.000 |
Why?
| | Swine | 1 | 1982 | 428 | 0.000 |
Why?
| | Muscle Proteins | 1 | 1982 | 343 | 0.000 |
Why?
|
|
Kelly Jr's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
|